Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 6 |
| List of Tables | 8 | 2 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Generics in Antivirals Market to 2018 - Market Overview | 12 | 11 |
| Introduction | 12 | 2 |
| Generic in Antivirals Market, Global Revenues | 14 | 1 |
| Revenue | 14 | 2 |
| Revenue by Geography | 16 | 2 |
| Annual Cost of Treatment | 18 | 1 |
| Treatment Usage Pattern | 19 | 1 |
| Diseased Population | 20 | 1 |
| Treatment Seeking Population | 20 | 1 |
| Diagnosed Population | 20 | 1 |
| Prescription Population | 21 | 1 |
| Drivers and Restraints for Generic Antiviral Market | 21 | 1 |
| Drivers | 21 | 1 |
| Restraints | 22 | 1 |
| Generics in Antivirals Market to 2018 - Geographical Landscape | 23 | 11 |
| The US | 23 | 1 |
| Revenue | 23 | 1 |
| Treatment Usage Pattern | 24 | 1 |
| Diseased Population | 25 | 1 |
| Treatment Seeking Population | 25 | 1 |
| Diagnosed Population | 25 | 1 |
| Prescription Population | 25 | 1 |
| Top Five Countries of Europe | 26 | 1 |
| Revenue | 26 | 1 |
| Segmentation by Country | 27 | 2 |
| Treatment Usage Pattern | 29 | 1 |
| Diseased Population | 30 | 1 |
| Treatment Seeking Population | 30 | 1 |
| Diagnosed Population | 30 | 1 |
| Prescription Population | 30 | 1 |
| Japan | 31 | 1 |
| Revenue | 31 | 1 |
| Treatment Usage Pattern | 32 | 1 |
| Diseased Population | 33 | 1 |
| Treatment Seeking Population | 33 | 1 |
| Diagnosed Population | 33 | 1 |
| Prescription Population | 33 | 1 |
| Generics in Antiviral Market to 2018 - Therapeutic Landscape | 34 | 52 |
| Global Generic HIV Therapeutics Market | 34 | 1 |
| Introduction | 34 | 1 |
| Revenue | 35 | 3 |
| Revenue by Country | 38 | 2 |
| Annual Cost of Treatment | 40 | 1 |
| Treatment Flow Algorithm | 41 | 1 |
| Treatment Usage Pattern | 42 | 1 |
| Diseased Population | 43 | 1 |
| Treatment Seeking Population | 43 | 1 |
| Diagnosed Population | 43 | 1 |
| Prescription Population | 43 | 1 |
| Drivers and Restraints for Generic HIV Market | 44 | 1 |
| Drivers | 44 | 1 |
| Restraints | 45 | 1 |
| Global Generic Hepatitis Therapeutics Market | 45 | 1 |
| Introduction | 45 | 1 |
| Hepatitis A | 45 | 1 |
| Hepatitis B | 45 | 1 |
| Hepatitis C | 46 | 1 |
| Revenue | 47 | 2 |
| Revenue by Country | 49 | 2 |
| Annual Cost of Treatment | 51 | 1 |
| Treatment Flow Algorithm | 52 | 1 |
| Treatment Usage Pattern | 53 | 1 |
| Diseased Population | 54 | 1 |
| Treatment Seeking Population | 54 | 1 |
| Diagnosed Population | 54 | 1 |
| Prescription Population | 54 | 1 |
| Drivers and Restraints for Generic Hepatitis Market | 55 | 1 |
| Drivers | 55 | 1 |
| Restraints | 55 | 1 |
| Global Generic Herpes Therapeutics Market | 56 | 1 |
| Introduction | 56 | 1 |
| Types of Herpes Virus | 56 | 1 |
| Herpes Simplex Infections | 56 | 1 |
| Herpes Zoster Infections | 57 | 1 |
| Revenue | 58 | 2 |
| Revenue by Country | 60 | 2 |
| Annual Cost of Treatment | 62 | 1 |
| Treatment Flow Algorithm | 63 | 1 |
| Treatment Usage Pattern | 64 | 1 |
| Diseased Population | 65 | 1 |
| Treatment Seeking Population | 65 | 1 |
| Diagnosed Population | 65 | 1 |
| Prescription Population | 65 | 1 |
| Drivers and Restraints for Generics in Herpes Therapeutics Market | 66 | 1 |
| Drivers | 66 | 1 |
| Restraints | 66 | 1 |
| Global Generic Cytomegalovirus Therapeutics Market | 67 | 1 |
| Introduction | 67 | 1 |
| Congenital CMV Infection | 67 | 1 |
| CMV Infections in Transplant Recipients | 67 | 1 |
| CMV Infections in HIV/AIDS Patients | 67 | 1 |
| Revenue | 68 | 2 |
| Revenue by Geography | 70 | 2 |
| Annual Cost of Treatment | 72 | 1 |
| Treatment Usage Pattern | 73 | 1 |
| Diseased Population | 74 | 1 |
| Treatment Seeking Population | 74 | 1 |
| Diagnosed Population | 74 | 1 |
| Prescription Population | 74 | 1 |
| Drivers and Restraints for Cytomegalovirus Therapeutics Market | 75 | 1 |
| Drivers | 75 | 1 |
| Restraints | 75 | 1 |
| Global Generic Influenza Market | 76 | 1 |
| Introduction | 76 | 1 |
| Revenue | 77 | 2 |
| Revenue by Geography | 79 | 2 |
| Annual Cost of Treatment | 81 | 1 |
| Treatment Flow Algorithm | 82 | 1 |
| Treatment Usage Pattern | 83 | 1 |
| Diseased Population | 84 | 1 |
| Treatment Seeking Population | 84 | 1 |
| Diagnosed Population | 84 | 1 |
| Prescription Population | 84 | 1 |
| Drivers and Restraints for Influenza Therapeutics Market | 85 | 1 |
| Drivers | 85 | 1 |
| Restraints | 85 | 1 |
| Generics in Antivirals Market to 2018 - Major Marketed Drugs Analysis | 86 | 11 |
| Major Generic Drugs in Antivirals Market | 86 | 1 |
| Ribavirin | 86 | 1 |
| Overview | 86 | 1 |
| Acyclovir | 86 | 1 |
| Mechanism of Action | 86 | 1 |
| Valacyclovir | 87 | 1 |
| Overview | 87 | 1 |
| Mechanism of Action | 87 | 1 |
| Famciclovir | 87 | 1 |
| Overview | 87 | 1 |
| Mechanism of Action | 87 | 1 |
| Penciclovir | 87 | 1 |
| Overview | 87 | 1 |
| Mechanism of Action | 87 | 1 |
| Didanosine | 88 | 1 |
| Overview | 88 | 1 |
| Mechanism of Action | 88 | 1 |
| Lamivudine | 88 | 1 |
| Overview | 88 | 1 |
| Mechanism of Action | 88 | 1 |
| Stavudine | 88 | 1 |
| Overview | 88 | 1 |
| Mechanism of Action | 88 | 1 |
| Zidovudine | 89 | 1 |
| Overview | 89 | 1 |
| Mechanism of Action | 89 | 1 |
| Zalcitabine | 89 | 1 |
| Overview | 89 | 1 |
| Mechanism of Action | 89 | 1 |
| Amantadine | 89 | 1 |
| Overview | 89 | 1 |
| Mechanism of Action | 89 | 1 |
| Rimantadine | 90 | 1 |
| Overview | 90 | 1 |
| Mechanism of Action | 90 | 1 |
| Ganciclovir | 90 | 1 |
| Overview | 90 | 1 |
| Mechanism of Action | 90 | 1 |
| Foscarnet | 90 | 1 |
| Overview | 90 | 1 |
| Mechanism of Action | 90 | 1 |
| Major Marketed Products Expecting Loss of Patent Exclusivity | 91 | 1 |
| Introduction | 91 | 1 |
| Baraclude | 92 | 1 |
| Overview | 92 | 1 |
| Viread | 92 | 1 |
| Overview | 92 | 1 |
| Mechanism of Action | 92 | 1 |
| Combivir | 93 | 1 |
| Overview | 93 | 1 |
| Mechanism of Action | 93 | 1 |
| Sustiva | 93 | 1 |
| Overview | 93 | 1 |
| Mechanism of Action | 93 | 1 |
| Kaletra | 93 | 1 |
| Overview | 93 | 1 |
| Mechanism of Action | 93 | 1 |
| Reyataz | 94 | 1 |
| Overview | 94 | 1 |
| Mechanism of Action | 94 | 1 |
| Epzicom | 94 | 1 |
| Overview | 94 | 1 |
| Mechanism of Action | 94 | 1 |
| Prezista | 94 | 1 |
| Overview | 94 | 1 |
| Mechanism of Action | 95 | 1 |
| Valcyte | 95 | 1 |
| Overview | 95 | 1 |
| Mechanism of Action | 95 | 1 |
| Tamiflu | 95 | 1 |
| Overview | 95 | 1 |
| Mechanism of Action | 95 | 1 |
| Atripla | 95 | 1 |
| Overview | 95 | 1 |
| Mechanism of Action | 96 | 1 |
| Truvada | 96 | 1 |
| Overview | 96 | 1 |
| Mechanism of Action | 96 | 1 |
| Generics in Antivirals Market to 2018 - Competitive Landscape | 97 | 4 |
| Competitive Profiling | 97 | 1 |
| Teva Pharmaceuticals | 97 | 1 |
| Overview | 97 | 1 |
| SWOT Analysis | 97 | 1 |
| Aurobindo Pharma Ltd | 98 | 1 |
| Overview | 98 | 1 |
| SWOT Analysis | 98 | 1 |
| Watson Pharmaceuticals | 99 | 1 |
| Overview | 99 | 1 |
| SWOT Analysis | 99 | 1 |
| Mylan Inc | 100 | 1 |
| Overview | 100 | 1 |
| SWOT Analysis | 100 | 1 |
| Generics in Antivirals Market to 2018 - Strategic Consolidations | 101 | 4 |
| Generics in Antivirals Market: Major Deals | 101 | 1 |
| Gilead Sciences Extends Licensing Agreement with Matrix Laboratories for Tenofovir, Elvitegravir, Cobicistat and Quad | 101 | 1 |
| Bristol-Myers Squibb Enters Into Co-Marketing Agreement with Matrix Laboratories | 101 | 1 |
| Tibotec Pharmaceuticals Enters Into Licensing Agreement with Matrix Laboratories for TMC278 | 102 | 1 |
| Watson Pharmaceuticals Acquires Specifar Pharmaceuticals | 102 | 1 |
| Watson Enters into Licensing Agreement with Natco | 102 | 1 |
| Apotex Acquires Lareq Pharma from Industria Quimica Y Farmaceutica | 102 | 1 |
| Apotex Acquires Topgen from Zambon | 103 | 1 |
| Teva Pharmaceutical Industries Acquires Taiyo Pharmaceutical Industry | 103 | 1 |
| Teva Pharmaceutical Industries Acquires Corporacion Infarmasa | 103 | 1 |
| Teva Pharmaceutical Industries Completes Acquisition of ratiopharm | 103 | 1 |
| Teva Pharmaceutical Acquires Barr Pharmaceuticals | 103 | 1 |
| Teva Pharmaceutical Industries Signs Joint Venture Agreement with Kowa Company | 104 | 1 |
| Teva Pharmaceutical Acquires Bentley Pharmaceuticals | 104 | 1 |
| Generics in Antivirals Market to 2018 - Appendix | 105 | 6 |
| Market Definitions | 105 | 1 |
| Abbreviations | 105 | 1 |
| Sources | 106 | 1 |
| Research Methodology | 106 | 5 |
| Coverage | 107 | 1 |
| Secondary Research | 107 | 1 |
| Primary Research | 107 | 1 |
| Forecast | 108 | 1 |
| Epidemiology-based Forecasting | 108 | 2 |
| Expert Panel Validation | 110 | 1 |
| Contact Us | 110 | 1 |
| Disclaimer | 110 | 1 |